restless legs syndrome
Neurology · 2006–2008
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pramipexole hydrochloride Treatment of severe idiopathic (primary) Restless Legs Syndrome in patients who meet all four diagnostic criteria and have a baseline International Restless… | Nov 2008 | Recommended with restriction | no section in document |
| pramipexole hydrochloride Treatment of severe, idiopathic Restless Legs Syndrome (RLS) in patients who meet diagnostic criteria and have a baseline International Restless Legs Syndrome… | Jul 2007 | Recommended | no section in document |
| pramipexole hydrochloride Treatment of severe, idiopathic Restless Legs Syndrome (RLS) in patients who meet diagnostic criteria and have a baseline International Restless Legs Syndrome… | Jul 2007 | Recommended | no section in document |
| ropinirole Treatment of severe primary restless legs syndrome in patients scoring ≥21 on the International Restless Legs Severity Scale and meeting the four IRLSSG… | Mar 2006 | Not recommended | no section in document |
| ropinirole Treatment of severe primary restless legs syndrome in patients with an International Restless Legs Severity Scale (IRLS) score ≥21 who meet diagnostic criteria… | Mar 2006 | Not recommended | no section in document |
| pramipexole hydrochloride Symptomatic treatment of moderate to very severe, idiopathic Restless Legs Syndrome (RLS) in patients with baseline International Restless Legs Syndrome Rating… | Nov 2006 | Not recommended | no section in document |
| pramipexole hydrochloride Symptomatic treatment of moderate to very severe, idiopathic restless legs syndrome (RLS) in patients with baseline International Restless Legs Syndrome Rating… | Nov 2006 | Not recommended | no section in document |
What the PBS pays
$29M in government benefit over 2024–25, across 1,143,962 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pramipexole | $14.4M |
| pramipexole hydrochloride | $14.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.